Sanofi (NASDAQ:SNY) Stock Holdings Cut by Signaturefd LLC

Signaturefd LLC lessened its position in Sanofi (NASDAQ:SNY) by 13.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,484 shares of the company’s stock after selling 4,837 shares during the period. Signaturefd LLC’s holdings in Sanofi were worth $1,516,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Clearbridge Investments LLC raised its position in Sanofi by 8.4% in the third quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock worth $9,904,000 after acquiring an additional 14,362 shares in the last quarter. Dynamic Advisor Solutions LLC bought a new stake in shares of Sanofi in the 4th quarter worth approximately $2,104,000. Soros Fund Management LLC acquired a new stake in Sanofi during the third quarter valued at approximately $11,533,000. International Assets Investment Management LLC bought a new stake in Sanofi during the fourth quarter worth approximately $4,704,000. Finally, Clear Street Markets LLC grew its position in Sanofi by 352.8% in the third quarter. Clear Street Markets LLC now owns 130,183 shares of the company’s stock worth $6,983,000 after buying an additional 101,430 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $46.30 on Monday. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock has a market cap of $117.12 billion, a PE ratio of 19.62, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. The business has a fifty day simple moving average of $47.52 and a 200-day simple moving average of $48.54.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. On average, sell-side analysts anticipate that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. This is a boost from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is currently 58.47%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SNY. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley initiated coverage on Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.